Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells

The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies durvalumab, atezolimuab, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibbons Johnson, Rachel M., Dong, Haidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554355/
https://www.ncbi.nlm.nih.gov/pubmed/28848559
http://dx.doi.org/10.3389/fimmu.2017.00961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554355/
https://www.ncbi.nlm.nih.gov/pubmed/28848559
http://dx.doi.org/10.3389/fimmu.2017.00961

Ejemplares similares